dehydroepiandrosterone has been researched along with Pulmonary Hypertension in 20 studies
Dehydroepiandrosterone: A major C19 steroid produced by the ADRENAL CORTEX. It is also produced in small quantities in the TESTIS and the OVARY. Dehydroepiandrosterone (DHEA) can be converted to TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE. Most of DHEA is sulfated (DEHYDROEPIANDROSTERONE SULFATE) before secretion.
dehydroepiandrosterone : An androstanoid that is androst-5-ene substituted by a beta-hydroxy group at position 3 and an oxo group at position 17. It is a naturally occurring steroid hormone produced by the adrenal glands.
| Excerpt | Relevance | Reference |
|---|---|---|
| "It was previously shown that dehydroepiandrosterone (DHEA) reverses chronic hypoxia-induced pulmonary hypertension (PH) in rats, but whether DHEA can improve the clinical and hemodynamic status of patients with PH associated to chronic obstructive pulmonary disease (PH-COPD) has not been studied whereas it is a very severe poorly treated disease." | 9.16 | Dehydroepiandrosterone (DHEA) improves pulmonary hypertension in chronic obstructive pulmonary disease (COPD): a pilot study. ( Baulieu, EÉ; Billes, MA; Doutreleau, S; Dromer, C; Dumas de La Roque, E; Fayon, M; Jougon, J; Kraemer, JP; Marthan, R; Metivier, AC; Moore, N; Savineau, JP, 2012) |
| " To test our hypothesis that combining two drugs useful in experimental pulmonary hypertension, statins and dehydroepiandrosterone sulfate (DHEA S), is more effective than either agent alone, we induced pulmonary hypertension in adult male rats by exposing them to hypoxia (10%O2) for 3 weeks." | 8.12 | Simvastatin and dehydroepiandrosterone sulfate effects against hypoxic pulmonary hypertension are not additive. ( Chalupský, K; D Uris Ova, J; Hampl, V; Kaftanová, B; Krása, K; Miková, D; Minaříkova, M; Srbová, M; Vajnerova, O, 2022) |
| "It has been reported that dehydroepiandrosterone is a pulmonary vasodilator and inhibits chronic hypoxia-induced pulmonary hypertension." | 7.74 | Dehydroepiandrosterone upregulates soluble guanylate cyclase and inhibits hypoxic pulmonary hypertension. ( Fagan, KA; Gebb, SA; Golembeski, SM; Homma, N; Imamura, M; Karoor, V; Limbird, J; McMurtry, IF; Nagaoka, T; Oka, M; Sakao, E, 2007) |
| "It was previously shown that dehydroepiandrosterone (DHEA) reverses chronic hypoxia-induced pulmonary hypertension (PH) in rats, but whether DHEA can improve the clinical and hemodynamic status of patients with PH associated to chronic obstructive pulmonary disease (PH-COPD) has not been studied whereas it is a very severe poorly treated disease." | 5.16 | Dehydroepiandrosterone (DHEA) improves pulmonary hypertension in chronic obstructive pulmonary disease (COPD): a pilot study. ( Baulieu, EÉ; Billes, MA; Doutreleau, S; Dromer, C; Dumas de La Roque, E; Fayon, M; Jougon, J; Kraemer, JP; Marthan, R; Metivier, AC; Moore, N; Savineau, JP, 2012) |
| " To test our hypothesis that combining two drugs useful in experimental pulmonary hypertension, statins and dehydroepiandrosterone sulfate (DHEA S), is more effective than either agent alone, we induced pulmonary hypertension in adult male rats by exposing them to hypoxia (10%O2) for 3 weeks." | 4.12 | Simvastatin and dehydroepiandrosterone sulfate effects against hypoxic pulmonary hypertension are not additive. ( Chalupský, K; D Uris Ova, J; Hampl, V; Kaftanová, B; Krása, K; Miková, D; Minaříkova, M; Srbová, M; Vajnerova, O, 2022) |
| " Dehydroepiandrosterone (DHEA) effectively treats experimental pulmonary hypertension in chronically hypoxic and monocrotaline-injected rats." | 3.79 | Dehydroepiandrosterone restores right ventricular structure and function in rats with severe pulmonary arterial hypertension. ( Abe, K; Alzoubi, A; Fagan, KA; McMurtry, IF; O'Neill, KD; Oka, M; Rocic, P; Toba, M, 2013) |
| "It has been reported that dehydroepiandrosterone is a pulmonary vasodilator and inhibits chronic hypoxia-induced pulmonary hypertension." | 3.74 | Dehydroepiandrosterone upregulates soluble guanylate cyclase and inhibits hypoxic pulmonary hypertension. ( Fagan, KA; Gebb, SA; Golembeski, SM; Homma, N; Imamura, M; Karoor, V; Limbird, J; McMurtry, IF; Nagaoka, T; Oka, M; Sakao, E, 2007) |
| "To investigate the effects of dehydroepiandrosterone (DHEA) on Ca(2+)-activated K(+) (K(Ca)) channel and mean pulmonary arterial pressure (mPAP) in rats with chronic pulmonary hypertension." | 3.72 | [Effect of dehydroepiandrosterone on Ca(2+)-activated K+ channel of pulmonary arterial smooth muscle cells in pulmonary hypertensive rats]. ( Chen, WB; Chen, Z; Cheng, DY; Xiao, XR, 2004) |
| "Dehydroepiandrosterone (DHEA) is a steroid hormone derived from cholesterol synthesized by the adrenal glands." | 2.49 | Role of DHEA in cardiovascular diseases. ( Dumas de la Roque, E; Marthan, R; Savineau, JP, 2013) |
| "Dehydroepiandrosterone (DHEA) is a steroid hormone shown to reverse vascular remodeling in systemic vessels." | 1.37 | Dehydroepiandrosterone inhibits the Src/STAT3 constitutive activation in pulmonary arterial hypertension. ( Bisserier, M; Bonnet, S; Courboulin, A; Jacob, MH; Meloche, J; Paulin, R, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (30.00) | 29.6817 |
| 2010's | 13 (65.00) | 24.3611 |
| 2020's | 1 (5.00) | 2.80 |
| Authors | Studies |
|---|---|
| Krása, K | 3 |
| Vajnerova, O | 3 |
| D Uris Ova, J | 3 |
| Minaříkova, M | 3 |
| Miková, D | 3 |
| Srbová, M | 3 |
| Chalupský, K | 3 |
| Kaftanová, B | 3 |
| Hampl, V | 3 |
| Guignabert, C | 1 |
| de Man, F | 1 |
| Lombès, M | 1 |
| Badlam, JB | 1 |
| Austin, ED | 1 |
| Klinge, CM | 1 |
| Clark, BJ | 1 |
| Prough, RA | 1 |
| Zhang, YT | 1 |
| Xue, JJ | 1 |
| Wang, Q | 1 |
| Cheng, SY | 1 |
| Chen, ZC | 1 |
| Li, HY | 1 |
| Shan, JJ | 1 |
| Cheng, KL | 1 |
| Zeng, WJ | 1 |
| Alzoubi, A | 2 |
| Toba, M | 1 |
| Abe, K | 1 |
| O'Neill, KD | 1 |
| Rocic, P | 1 |
| Fagan, KA | 3 |
| McMurtry, IF | 4 |
| Oka, M | 3 |
| Dumas de la Roque, E | 4 |
| Quignard, JF | 1 |
| Ducret, T | 1 |
| Dahan, D | 1 |
| Courtois, A | 1 |
| Begueret, H | 2 |
| Marthan, R | 4 |
| Savineau, JP | 5 |
| Lahm, T | 1 |
| Tuder, RM | 1 |
| Petrache, I | 1 |
| Chettimada, S | 1 |
| Joshi, SR | 1 |
| Gebb, SA | 2 |
| Gupte, R | 1 |
| Gupte, SA | 1 |
| Pugh, ME | 1 |
| Hemnes, AR | 1 |
| Bonnet, S | 3 |
| Paulin, R | 1 |
| Meloche, J | 1 |
| Jacob, MH | 1 |
| Bisserier, M | 1 |
| Courboulin, A | 1 |
| Metivier, AC | 1 |
| Billes, MA | 1 |
| Kraemer, JP | 1 |
| Doutreleau, S | 1 |
| Jougon, J | 1 |
| Moore, N | 1 |
| Fayon, M | 2 |
| Baulieu, EÉ | 3 |
| Dromer, C | 1 |
| Dumas-de-La-Roque, E | 1 |
| Dos Santos, P | 1 |
| Xiao, XR | 1 |
| Chen, WB | 1 |
| Cheng, DY | 1 |
| Chen, Z | 1 |
| Karoor, V | 2 |
| Homma, N | 2 |
| Nagaoka, T | 2 |
| Sakao, E | 1 |
| Golembeski, SM | 1 |
| Limbird, J | 1 |
| Imamura, M | 2 |
| Dubuis, E | 1 |
| Dessouroux, A | 1 |
| Akwa, Y | 1 |
| Taraseviciene-Stewart, L | 1 |
| Walker, LA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of Efficacy of Pharmacotherapy Treatment of COVID- 19 Infection Using Oral Levamisole and Formoterol+Budesonide Inhaler and Comparison of This Treatment Protocol With Standard National Treatment of the Disease[NCT04331470] | Phase 2/Phase 3 | 30 participants (Anticipated) | Interventional | 2020-04-04 | Recruiting | ||
| Double-blind, Randomised, Placebo-controlled Phase III Study of Dehydroepiandrosterone (DHEA) in Respiratory Pulmonary Hypertension in Adults[NCT00581087] | Phase 3 | 60 participants (Anticipated) | Interventional | 2007-01-31 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for dehydroepiandrosterone and Pulmonary Hypertension
| Article | Year |
|---|---|
Dehydroepiandrosterone Research: Past, Current, and Future.
Topics: Animals; Cardiovascular Physiological Phenomena; Dehydroepiandrosterone; Fertility Agents, Female; G | 2018 |
Progress in solving the sex hormone paradox in pulmonary hypertension.
Topics: Animals; Dehydroepiandrosterone; Estrogens; Familial Primary Pulmonary Hypertension; Female; Heart V | 2014 |
Development of pulmonary arterial hypertension in women: interplay of sex hormones and pulmonary vascular disease.
Topics: Animals; Dehydroepiandrosterone; Disease Models, Animal; Estrogens; Female; Gonadal Steroid Hormones | 2010 |
Dehydroepiandrosterone: A new treatment for vascular remodeling diseases including pulmonary arterial hypertension.
Topics: Animals; Apoptosis; Cell Proliferation; Constriction, Pathologic; Dehydroepiandrosterone; Disease Mo | 2010 |
Role of DHEA in cardiovascular diseases.
Topics: Age Factors; Animals; Cardiovascular Diseases; Dehydroepiandrosterone; Female; Humans; Hypertension, | 2013 |
1 trial available for dehydroepiandrosterone and Pulmonary Hypertension
| Article | Year |
|---|---|
Dehydroepiandrosterone (DHEA) improves pulmonary hypertension in chronic obstructive pulmonary disease (COPD): a pilot study.
Topics: Adult; Dehydroepiandrosterone; Exercise Test; Female; Hemodynamics; Humans; Hypertension, Pulmonary; | 2012 |
14 other studies available for dehydroepiandrosterone and Pulmonary Hypertension
| Article | Year |
|---|---|
Simvastatin and dehydroepiandrosterone sulfate effects against hypoxic pulmonary hypertension are not additive.
Topics: Animals; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Hypertension, Pulmonary; Hypoxia; M | 2022 |
Simvastatin and dehydroepiandrosterone sulfate effects against hypoxic pulmonary hypertension are not additive.
Topics: Animals; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Hypertension, Pulmonary; Hypoxia; M | 2022 |
Simvastatin and dehydroepiandrosterone sulfate effects against hypoxic pulmonary hypertension are not additive.
Topics: Animals; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Hypertension, Pulmonary; Hypoxia; M | 2022 |
Simvastatin and dehydroepiandrosterone sulfate effects against hypoxic pulmonary hypertension are not additive.
Topics: Animals; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Hypertension, Pulmonary; Hypoxia; M | 2022 |
Simvastatin and dehydroepiandrosterone sulfate effects against hypoxic pulmonary hypertension are not additive.
Topics: Animals; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Hypertension, Pulmonary; Hypoxia; M | 2022 |
Simvastatin and dehydroepiandrosterone sulfate effects against hypoxic pulmonary hypertension are not additive.
Topics: Animals; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Hypertension, Pulmonary; Hypoxia; M | 2022 |
Simvastatin and dehydroepiandrosterone sulfate effects against hypoxic pulmonary hypertension are not additive.
Topics: Animals; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Hypertension, Pulmonary; Hypoxia; M | 2022 |
Simvastatin and dehydroepiandrosterone sulfate effects against hypoxic pulmonary hypertension are not additive.
Topics: Animals; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Hypertension, Pulmonary; Hypoxia; M | 2022 |
Simvastatin and dehydroepiandrosterone sulfate effects against hypoxic pulmonary hypertension are not additive.
Topics: Animals; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Hypertension, Pulmonary; Hypoxia; M | 2022 |
ACE2 as therapy for pulmonary arterial hypertension: the good outweighs the bad.
Topics: Connective Tissue Diseases; Dehydroepiandrosterone; Female; Heart Diseases; Humans; Hypertension, Pu | 2018 |
Beyond oestrogens: towards a broader evaluation of the hormone profile in pulmonary arterial hypertension.
Topics: Connective Tissue Diseases; Dehydroepiandrosterone; Estrogens; Familial Primary Pulmonary Hypertensi | 2018 |
Dehydroepiandrosterone attenuates pulmonary artery and right ventricular remodeling in a rat model of pulmonary hypertension due to left heart failure.
Topics: Animals; Blotting, Western; Dehydroepiandrosterone; Disease Models, Animal; Echocardiography; Heart | 2019 |
Dehydroepiandrosterone restores right ventricular structure and function in rats with severe pulmonary arterial hypertension.
Topics: Animals; Apoptosis; Blood Pressure; Dehydroepiandrosterone; Fibrosis; Gene Expression; Heart Ventric | 2013 |
Beneficial effect of dehydroepiandrosterone on pulmonary hypertension in a rodent model of pulmonary hypertension in infants.
Topics: Analysis of Variance; Animals; Animals, Newborn; Arterial Pressure; Cell Proliferation; Dehydroepian | 2013 |
Glucose-6-phosphate dehydrogenase plays a critical role in hypoxia-induced CD133+ progenitor cells self-renewal and stimulates their accumulation in the lungs of pulmonary hypertensive rats.
Topics: AC133 Antigen; Administration, Oral; Animals; Antigens, CD; Cell Differentiation; Cell Hypoxia; Cell | 2014 |
Dehydroepiandrosterone inhibits the Src/STAT3 constitutive activation in pulmonary arterial hypertension.
Topics: Adult; Animals; Antihypertensive Agents; Apoptosis; Blotting, Western; Bone Morphogenetic Protein Re | 2011 |
Dehydroepiandrosterone (DHEA) prevents and reverses chronic hypoxic pulmonary hypertension.
Topics: Adjuvants, Immunologic; Administration, Oral; Animals; Blotting, Western; Calcium; Calcium Channels; | 2003 |
[Effect of dehydroepiandrosterone on Ca(2+)-activated K+ channel of pulmonary arterial smooth muscle cells in pulmonary hypertensive rats].
Topics: Adjuvants, Immunologic; Animals; Cell Hypoxia; Dehydroepiandrosterone; Disease Models, Animal; Hyper | 2004 |
Dehydroepiandrosterone upregulates soluble guanylate cyclase and inhibits hypoxic pulmonary hypertension.
Topics: Acetylcholine; Animals; Blotting, Western; Cyclic GMP; Dehydroepiandrosterone; Dehydroepiandrosteron | 2007 |
DHEA treatment of pulmonary hypertension: new insights into a complex mechanism.
Topics: Animals; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Guanylate Cyclase; Humans; Hyperten | 2007 |
DHEA decreases HIF-1alpha accumulation under hypoxia in human pulmonary artery cells: potential role in the treatment of pulmonary arterial hypertension.
Topics: Amino Acids, Dicarboxylic; Base Sequence; Cells, Cultured; Cobalt; Deferoxamine; Dehydroepiandroster | 2008 |
Involvement of RhoA/Rho kinase signaling in protection against monocrotaline-induced pulmonary hypertension in pneumonectomized rats by dehydroepiandrosterone.
Topics: Adjuvants, Immunologic; Animals; Blood Pressure; Dehydroepiandrosterone; Enzyme Activation; Gene Exp | 2008 |